Cadence files intravenous paracetamol for US approval
This article was originally published in Scrip
Executive Summary
Cadence Pharmaceuticals has submitted a marketing application for an intravenous formulation of acetaminophen (paracetamol) in the US, where it will be marketed as Acetavance.